Lee Shing Fung, Ng Ting Ying, Wong Frank Chi Sing, Tung Stewart Yuk
Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong, SAR, China.
Leuk Res Rep. 2017 Feb 28;7:23-28. doi: 10.1016/j.lrr.2017.02.002. eCollection 2017.
Multiple myeloma is a relatively uncommon plasma cell malignancy. Preclinical and clinical studies have suggested that aspirin might modify the risk of multiple myeloma. We performed a systematic review and meta-analysis of studies to examine the association between regular aspirin use and risk of multiple myeloma. Five observational studies including 332,660 adults were evaluated. The pooled estimate had a hazard ratio of 0.90 (95% confidence interval =0.58-1.39; P=0.638). Odds ratios from the two case-control studies were similar. The findings demonstrated that there was no significant association between aspirin use and the risk of multiple myeloma.
多发性骨髓瘤是一种相对罕见的浆细胞恶性肿瘤。临床前和临床研究表明，阿司匹林可能会改变多发性骨髓瘤的发病风险。我们对相关研究进行了系统综述和荟萃分析，以检验规律服用阿司匹林与多发性骨髓瘤发病风险之间的关联。评估了五项观察性研究，共纳入332,660名成年人。汇总估计的风险比为0.90（95%置信区间=0.58-1.39；P=0.638）。两项病例对照研究的比值比相似。研究结果表明，服用阿司匹林与多发性骨髓瘤发病风险之间无显著关联。
